Correlation Between Zenas BioPharma, and EnGene Holdings

Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and EnGene Holdings at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and EnGene Holdings into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zenas BioPharma, Common and enGene Holdings Common, you can compare the effects of market volatilities on Zenas BioPharma, and EnGene Holdings and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of EnGene Holdings. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and EnGene Holdings.

Diversification Opportunities for Zenas BioPharma, and EnGene Holdings

0.03

Correlation Coefficient

Zenas BioPharma,  EnGene Holdings

Significant diversification

The 3 months correlation between Zenas and EnGene is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and enGene Holdings Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on enGene Holdings Common and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with EnGene Holdings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of enGene Holdings Common has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and EnGene Holdings go up and down completely randomly.

Pair Corralation between Zenas BioPharma, and EnGene Holdings

Given the investment horizon of 90 days Zenas BioPharma, Common is expected to under-perform the EnGene Holdings. But the etf apears to be less risky and, when comparing its historical volatility, Zenas BioPharma, Common is 1.64 times less risky than EnGene Holdings. The etf trades about -0.11 of its potential returns per unit of risk. The enGene Holdings Common is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  1,046  in enGene Holdings Common on December 4, 2024 and sell it today you would lose (467.00) from holding enGene Holdings Common or give up 44.65% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	23.64%
Values	Daily Returns

Zenas BioPharma, Common  vs.  enGene Holdings Common

Zenas BioPharma, Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

enGene Holdings Common

Risk-Adjusted Performance

Very Weak

Over the last 90 days enGene Holdings Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, EnGene Holdings is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Zenas BioPharma, and EnGene Holdings

The main advantage of trading using opposite Zenas BioPharma, and EnGene Holdings positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, EnGene Holdings can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in EnGene Holdings will offset losses from the drop in EnGene Holdings' long position.

The idea behind Zenas BioPharma, Common and enGene Holdings Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.